MUDr. Hana Burianova
- Address
- Nova cesta 531/11, 74301 Bilovec, Czechia
MUDr. Hana Burianova - Cardiovascular Research Center
MUDr. Hana Burianova operates a specialized cardiovascular research facility focused on advancing treatment options for patients with complex cardiac conditions. The center demonstrates particular expertise in conducting Phase 3 clinical trials evaluating novel therapeutic approaches for heart failure and atrial fibrillation, two of the most prevalent and challenging cardiovascular disorders.
- Heart failure with preserved and mildly reduced ejection fraction (LVEF ≥40%)
- Prevention of cardioembolic events in atrial fibrillation patients
- Evaluation of combination therapies and novel anticoagulation strategies
The research center participates in pivotal international trials investigating innovative pharmacological interventions, including studies of vicadrostat combined with empagliflozin for heart failure management and comparative effectiveness trials of milvexian versus apixaban for stroke prevention in atrial fibrillation. This work contributes to developing evidence-based treatment protocols that may reduce cardiovascular mortality, hospitalization rates, and thromboembolic complications in high-risk patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MUDr. Hana Burianova
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bi 690517 | 2 | Unknown | 2024-10-18 | 2025-08-22 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.